The Safety Tolerability Pharmacokinetic Characteristics and Efficacy of XZP-5955 Tablets in Patients With NTRK or ROS1 Gene Fusion Locally Advanced or Metastatic Solid Tumors in a Single-arm Open-label Multi-center Phase I/II Clinical Study
Latest Information Update: 01 Sep 2022
At a glance
- Drugs XZP-5955 (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors XuanZhu Pharma
- 17 May 2022 Status changed from not yet recruiting to recruiting.
- 17 Aug 2021 New trial record